Italy's antitrust regulator fined Novartis and Roche €182.5 million for...

Italy's antitrust regulator fined Novartis and Roche €182.5 million for allegedly colluding to prevent the use of Roche's Avastin, a cancer drug, as a treatment for eye macular degeneration. The two pharmaceutical companies blocked distribution of Avastin in favor of a more expensive drug, Lucentis, which they marketed jointly for ...

Keep reading this article by becoming a member

barrier_image_OIC

Enjoy unrestricted access to Eyewear Intelligence

To continue reading this article subscribe now

  • Unlimited access to our highly trusted industry insights and analysis
  • Benchmark yourself against the market and competitors
  • Find inspiration to drive your business forward
  • Stay up to date with new business models and startups

If you aren’t ready to subscribe now, you can REGISTER FOR FREE. Already an Eyewear Intelligence subscriber? Sign in here.